The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WILMINGTON, Del., September 22, 2022--Phreesia, a leader in patient intake, outreach and activation, has named Alexandra Beneville as Vice President of Life Sciences Content Strategy. Beneville officially joined Phreesia on Aug. 1, 2022, from Phosphorus, a direct-to-consumer genomic testing company, where she had served as Vice President of Marketing since December 2021.
WILMINGTON, Del., September 16, 2022--Phreesia is proud to announce that Zeeshan Butt, PhD, a Director of Clinical Content, has been selected to serve a three-year term as a member of the National Quality Forum (NQF)’s Measure Applications Partnership (MAP) 2022-2023 Clinician Workgroup.